Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allurion Technologies Inc - SIC # 7372 - PREPACKAGED SOFTWARE
Ticker
Exchange
SIC #
Website
Latest Ticker
ALUR
New York
7372
https://www.allurion.com/en
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allurion Technologies Inc
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- Apr 17th, 2024 12:31 pm
Allurion Expands Virtual Care Suite to the United States
- Apr 4th, 2024 12:00 pm
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
- Mar 21st, 2024 12:00 pm
Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- Mar 13th, 2024 12:30 pm
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
- Mar 12th, 2024 12:00 pm
Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024
- Mar 4th, 2024 1:30 pm
Allurion to Participate in Cowen’s 44th Annual Health Care Conference
- Feb 20th, 2024 9:05 pm
Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
- Feb 8th, 2024 1:30 pm
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies
- Jan 29th, 2024 1:00 pm
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
- Jan 23rd, 2024 2:04 pm
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships
- Jan 17th, 2024 1:00 pm
Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities
- Jan 11th, 2024 1:00 pm
Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook
- Jan 8th, 2024 1:00 pm
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
- Jan 5th, 2024 1:00 pm
Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership
- Jan 2nd, 2024 1:00 pm
Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 1:00 pm
Allurion to Participate in the Jefferies London Healthcare Conference
- Nov 6th, 2023 9:05 pm
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023
- Nov 6th, 2023 1:00 pm
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
- Oct 11th, 2023 12:00 pm
Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023
- Oct 4th, 2023 12:00 pm
Scroll